EP1482922A4 - Agents for corneal or intrastromal administration to treat or prevent disorders of the eye - Google Patents

Agents for corneal or intrastromal administration to treat or prevent disorders of the eye

Info

Publication number
EP1482922A4
EP1482922A4 EP03711552A EP03711552A EP1482922A4 EP 1482922 A4 EP1482922 A4 EP 1482922A4 EP 03711552 A EP03711552 A EP 03711552A EP 03711552 A EP03711552 A EP 03711552A EP 1482922 A4 EP1482922 A4 EP 1482922A4
Authority
EP
European Patent Office
Prior art keywords
corneal
treat
eye
agents
prevent disorders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP03711552A
Other languages
German (de)
French (fr)
Other versions
EP1482922A1 (en
Inventor
Vicken Karageozian
David Castillejos
John Park
Gabriel Arthuro Carpio Aragon
Jose Luis Gutierres Flores
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vitreo Retinal Technologies Inc
Original Assignee
Vitreo Retinal Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vitreo Retinal Technologies Inc filed Critical Vitreo Retinal Technologies Inc
Publication of EP1482922A1 publication Critical patent/EP1482922A1/en
Publication of EP1482922A4 publication Critical patent/EP1482922A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
EP03711552A 2002-03-14 2003-03-14 Agents for corneal or intrastromal administration to treat or prevent disorders of the eye Withdrawn EP1482922A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36397902P 2002-03-14 2002-03-14
US363979P 2002-03-14
PCT/US2003/007700 WO2003077898A1 (en) 2002-03-14 2003-03-14 Agents for corneal or intrastromal administration to treat or prevent disorders of the eye

Publications (2)

Publication Number Publication Date
EP1482922A1 EP1482922A1 (en) 2004-12-08
EP1482922A4 true EP1482922A4 (en) 2005-06-08

Family

ID=28041849

Family Applications (1)

Application Number Title Priority Date Filing Date
EP03711552A Withdrawn EP1482922A4 (en) 2002-03-14 2003-03-14 Agents for corneal or intrastromal administration to treat or prevent disorders of the eye

Country Status (10)

Country Link
EP (1) EP1482922A4 (en)
JP (1) JP2005522464A (en)
KR (1) KR20040094793A (en)
CN (1) CN1642536A (en)
AU (2) AU2003213858A1 (en)
BR (1) BR0308403A (en)
CA (1) CA2478965A1 (en)
MX (1) MXPA04008776A (en)
RU (1) RU2363459C2 (en)
WO (1) WO2003077898A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030199574A1 (en) 2000-03-02 2003-10-23 Vitreo-Retinal Technologies, Inc. Treatment of ophthalmic disorders using urea and urea derivatives
CN101231121B (en) * 2007-01-24 2012-06-13 泰州乐金电子冷机有限公司 Pallet stretching-out device for refrigerator
JP5858435B2 (en) * 2010-03-12 2016-02-10 国立研究開発法人理化学研究所 Clarification reagent for biological materials and use thereof
CN103562702A (en) 2011-05-20 2014-02-05 独立行政法人理化学研究所 Clarifying reagent for biological materials and use thereof
EP3035026A4 (en) 2013-08-14 2017-04-26 Riken Composition for preparing biomaterial with excellent light-transmitting property, and use thereof
DE102013110608A1 (en) * 2013-09-26 2015-03-26 Florian Lang Substance for inhibiting tissue calcification, tissue fibrosis and age-associated diseases
CN110237238A (en) * 2019-08-02 2019-09-17 山东省眼科研究所 MANF is promoting the application in corneal injury reparation

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000051620A1 (en) * 1999-03-02 2000-09-08 Vitreo-Retinal Technologies, Inc. Agents for intravitreal administration to treat or prevent disorders of the eye
WO2003068166A2 (en) * 2002-02-13 2003-08-21 Vitreo-Retinal Technologies, Inc. Treatment of ophthalmic disorders using urea and urea derivatives

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5470881A (en) * 1993-09-09 1995-11-28 West Virginia University Research Corporation Urea ophthalmic ointment and solution

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000051620A1 (en) * 1999-03-02 2000-09-08 Vitreo-Retinal Technologies, Inc. Agents for intravitreal administration to treat or prevent disorders of the eye
WO2003068166A2 (en) * 2002-02-13 2003-08-21 Vitreo-Retinal Technologies, Inc. Treatment of ophthalmic disorders using urea and urea derivatives

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO03077898A1 *

Also Published As

Publication number Publication date
AU2003213858A1 (en) 2003-09-29
BR0308403A (en) 2005-01-18
CA2478965A1 (en) 2003-09-25
MXPA04008776A (en) 2005-04-19
EP1482922A1 (en) 2004-12-08
RU2004129761A (en) 2005-06-10
RU2363459C2 (en) 2009-08-10
AU2009201897B2 (en) 2011-09-15
WO2003077898A1 (en) 2003-09-25
AU2009201897A1 (en) 2009-06-04
KR20040094793A (en) 2004-11-10
JP2005522464A (en) 2005-07-28
CN1642536A (en) 2005-07-20

Similar Documents

Publication Publication Date Title
GB0404693D0 (en) Pharmaceutical preparations for the treatment of ocular surface and other disorders
HK1092367A1 (en) Combination therapy for the treatment of ocular neovascular disorders
FI9630U1 (en) A system for laser treatment of the retina of a patient&#39;s eye
IL230241A (en) Retinal derivatives and methods for the use thereof for the treatment of visual disorders
WO2006071548A3 (en) Aminopyrazine analogs for treating glaucoma and other rho kinase-mediated diseases
TW200833341A (en) 6-aminoimidazo[1,2-b]pyridazine analogs as rho kinase inhibitors for the treatment of rho kinase-mediated diseases and conditions
IL190295A0 (en) Combination therapy comprising substituted oxazolidinones for the prevention and treatment of cerebral circulatory disorders
WO2008029276A3 (en) Compositions and methods for the treatment of ophthalmic disease
GB2402674B (en) Compositions and methods for the treatment of glaucoma or ocular hypertension
EP1631297A4 (en) Treatment of immune-mediated disorders with active vitamin d compounds alone or in combination with other therapeutic agents
WO2004012762A3 (en) Method and composition for protecting neuronal tissue from damage induced by elevated glutamate levels
HUP0401605A3 (en) Integrin inhibitors for the treatment of eye diseases
MX2007004030A (en) Polyamine analogs as therapeutic agents for ocular diseases.
WO2002079169A8 (en) Cyano-substituted dihydropyrimidine compounds and their use to treat diseases
PL371281A1 (en) Methods and compositions for the treatment of eye diseases
DK1614419T3 (en) AGENTS FOR THE PREVENTION / TREATMENT OF RETINAL NERVOUS DISEASES, CONTAINING ALKYLETHER DERIVATIVES OR SALTS THEREOF
EP1542664A4 (en) Methods and compositions for treatment of macular and retinal disease
PL378210A1 (en) Use of steroids to treat ocular disorders
EP1482922A4 (en) Agents for corneal or intrastromal administration to treat or prevent disorders of the eye
EP1406648A4 (en) The use of angiotensin i derivative as an agent for the treatment and prevention of infarction-related cardiac injuries and disorders
AU2003291253A1 (en) Scleral implants for treatment of eye disorders
HK1057332A1 (en) Use of 3-benzoylphenylacetic acid derivatives for the treatment of retinal disorders
CA2414586A1 (en) Agent for therapeutic treatment of optic nerve diseases and the like
SI1362590T1 (en) Use of cilobradine or the pharmaceutically acceptable salts thereof for the treatment or prevention of heart failure
IL163938A0 (en) Agents for corneal or intrastromal administration to treat or prevent disorders of the eye

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20040901

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

A4 Supplementary search report drawn up and despatched

Effective date: 20050421

RIC1 Information provided on ipc code assigned before grant

Ipc: 7A 61P 27/06 B

Ipc: 7A 61K 31/40 B

Ipc: 7A 61K 31/17 A

17Q First examination report despatched

Effective date: 20060119

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

RTI1 Title (correction)

Free format text: AGENTS FOR CORNEAL ADMINISTRATION TO TREAT OR PREVENT DISORDERS OF THE EYE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20100310